The present disclosure relates to a respiratory treatment device, and in particular, to an orientation dependent oscillating positive expiratory pressure (“OPEP”) device.
Each day, humans may produce upwards of 30 milliliters of sputum, which is a type of bronchial secretion. Normally, an effective cough is sufficient to loosen secretions and clear them from the body's airways. However, for individuals suffering from more significant bronchial obstructions, such as collapsed airways, a single cough may be insufficient to clear the obstructions.
OPEP therapy represents an effective bronchial hygiene technique for the removal of bronchial secretions in the human body and is an important aspect in the treatment and continuing care of patients with bronchial obstructions, such as those suffering from chronic obstructive lung disease. It is believed that OPEP therapy, or the oscillation of exhalation pressure at the mouth during exhalation, effectively transmits an oscillating back pressure to the lungs, thereby splitting open obstructed airways and loosening the secretions contributing to bronchial obstructions.
OPEP therapy is an attractive form of treatment because it can be easily taught to most hospitalized patients, and such patients can assume responsibility for the administration of OPEP therapy throughout their hospitalization and also once they have returned home. To that end, a number of portable OPEP devices have been developed.
In one aspect, a respiratory device includes a housing enclosing a chamber and an orientation indicator moveable with respect to the housing between a first position indicative of an orientation of the housing predetermined to be suitable for the operation of the respiratory device, and a second position indicative of an orientation of the housing predetermined to be less suitable for operation of the respiratory device. The orientation indicator may be positioned in a location on the respiratory device visible to a user during the operation of the respiratory device.
In another aspect, the respiratory device may be an OPEP device. Alternatively, the respiratory device may be a nebulizer.
In another aspect, an OPEP device includes a housing enclosing a chamber, a chamber inlet, a chamber outlet, and a channel positioned in an exhalation flow path between the chamber inlet and the chamber outlet. An air flow regulator is moveable with respect to the channel. Furthermore, an orientation indicator is moveable with respect to the housing between a first position indicative of an orientation of the housing predetermined to be suitable for administration of OPEP therapy to a user, and a second position indicative of an orientation of the housing predetermined to be less suitable for administration of OPEP therapy to the user. The orientation indicator may be positioned in a location on the OPEP device visible to the user during the administration of OPEP therapy.
In another aspect, the orientation indicator moves in response to a change in the orientation of the housing. A weight of the orientation indicator may bias the orientation indicator in the direction of gravity. As such, the orientation indicator may be moveable in at least one direction.
In another aspect, the respiratory device or the OPEP device may include a capsule enclosing the orientation indicator. The capsule may include an indicia for identifying a portion of the capsule in which the presence of the orientation indicator indicates an orientation of the housing predetermined to be suitable for the operation of the respiratory device, or for the administration of OPEP therapy. The capsule may be shaped so that the orientation indicator moves to the first position in response to a change in the orientation of the housing to an orientation predetermined to be suitable for operation of the respiratory device, or for the administration of OPEP therapy.
In yet another aspect, the orientation indicator may be a sphere. The orientation indicator may also be a fluid. Alternatively, the orientation indicator may be in the form of a meter needle.
In another aspect, the chamber inlet may be configured to receive exhaled air into the chamber, while the chamber outlet may be configured to permit exhaled air to exit the chamber.
In a further aspect, a respiratory device includes a housing enclosing a chamber and an orientation indicator configured to provide visual or auditory feedback to a user indicative of the suitability of the orientation of housing predetermined to be suitable for the administration of the respiratory therapy.
In another aspect, the orientation indicator includes a micro electro-mechanical system gyroscope configured to sense the orientation of the housing. The orientation indicator may also include at least one light for indicating the suitability of the orientation of the housing for the administration of OPEP therapy. The orientation may also include an audio signaling device for indicating the suitability of the orientation of the housing for the administration of OPEP therapy.
In yet another aspect, a method of administering orientation dependent OPEP therapy includes passing a flow of exhaled air along an exhalation flow path defined between an inlet and an outlet of a chamber in an OPEP device, maintaining an air flow regulator in a channel positioned in the exhalation flow path for restricting the flow of exhaled air through the channel, and moving the air flow regulator in repose to the flow of exhaled air repeatedly between a first position where the flow of exhaled air is restricted and a second position where the flow of exhaled air is less restricted. The method also involves the step of orienting the OPEP device based on feedback provided by an orientation indicator on the OPEP device. The orientation indicator may provide either visual feedback or auditory feedback to indicate the suitability of the orientation of the OPEP device for the administration of OPEP therapy.
In a further aspect, a method of administering nebulizer therapy includes providing a liquid stored in a reservoir, providing a source of pressurized gas, and aerosolizing the liquid with the pressurized gas. The method further includes orienting the nebulizer based on feedback provided by an orientation indicator provided on the nebulizer. The orientation indicator may provide either visual feedback or auditory feedback to indicate the suitability of the orientation of the reservoir for the administration of nebulizer therapy.
OPEP therapy is very effective within a range of operating conditions. For example, an adult human may have an exhalation flow rate ranging from 10 to 60 liters per minute, and may maintain a static exhalation pressure in the range of 10 to 20 cm H2O. Within these parameters, OPEP therapy is believed to be most effective when changes in the exhalation pressure range from 5 to 20 cm H2O oscillating at a frequency of 10 to 40 Hz. In contrast, an adolescent may have a much lower exhalation flow rate, and may maintain a lower static exhalation pressure, thereby altering the operating conditions most effective for OPEP therapy. Likewise, the ideal operating conditions for an athlete may differ from those of an adult. As described below, the disclosed OPEP device is configurable and provides feedback to the user so that ideal operating conditions may be selected and maintained.
Referring first to
As shown, the housing 102 is generally egg-shaped. However, a housing of any shape could be used. Furthermore, the chamber inlet 104 and the chamber outlet 106 could be any shape or series of shapes, such as a plurality of circular passages or linear slots. Likewise, the chamber inlet 104 and the chamber outlet 106 may be located elsewhere on the housing 102. More importantly, it should be appreciated that the cross-sectional area of the chamber inlet 104 is but one of the factors influencing the ideal operating conditions described above.
Referring to
An exhalation flow path, identified by dotted line 111, is defined between the chamber inlet 104 and the chamber outlet 106. The OPEP device 100 also includes an orientation indicator 158 to provide a user with visual feedback of the orientations of the OPEP device 100 suitable and/or ideal for providing OPEP therapy, as explained in greater detail below. In addition, a transparent window 160 may be included with the housing 102 to permit the user to view the components contained therein, such as those that may be selectively adjusted and/or replaced to obtain the desired operating conditions.
As shown in
Referring to
Those skilled in the art will appreciate that the shape of the channel 118 could be altered to achieve a different range of restriction. For example, a portion of the channel 118 in
Turning to
In operation, the OPEP device 100 administers OPEP therapy to a user while he or she exhales into the chamber inlet 104 through the mouthpiece 108. When the OPEP device 100 is positioned in an upright orientation, as shown in
In the second position, the air flow regulator 120 is lifted away from the resting position near the bottom of the channel 118. Depending on the shape and size of the air flow regulator 120 and/or the channel 118, the air flow regulator 120 may roll, slide, or jump to the second position. With the air flow regulator 120 in the second position, the flow of air through the channel 118 is less restricted than the flow of air through the channel 118 when the air flow regulator 120 is in the first position. As such, more air is permitted to traverse the channel 118 and exit the chamber outlet 106. In this way, the weight of the air flow regulator 120 offers a resistance to the flow of exhaled air through the channel 118 during exhalation.
After the airflow regulator 120 moves to the second position, and the flow of air through the channel 118 increases, the pressure in the chamber 114 begins to drop. As the pressure decreases, the force acting on the portion of the air flow regulator 120 restricting the flow of air through the channel 118 also decreases. When this force drops below the force of gravity acting on the air flow regulator 120, the air flow regulator 120 returns to the first position, thereby increasing the restriction on the flow of air through the channel 118, and causing the pressure in the chamber 114 to rise again. As a user continues to exhale, this process repeats itself, effectively generating an oscillating pressure in the chamber 114. This oscillating pressure is in turn transmitted back through the chamber inlet 104 and into the respiratory system of the user, providing him or her with OPEP therapy.
As previously explained, the weight of the air flow regulator 120 offers a resistance to the flow of air through the channel 118. While the air flow regulator 120 is in the first position, the force of gravity acting on the air flow regulator 120 is balanced by the force derived from the exhalation pressure in the chamber 114 and the normal force from the channel 118 acting on the air flow regulator 120. Accordingly, if the orientation of the channel 118 were to change, the magnitude and direction of the normal force from the channel 118 would change, as would the direction of the force acting on the air flow regulator 120 derived from the exhalation pressure in the chamber 114. The direction and magnitude of gravitational forces acting on the air flow regulator 120, however, would remain unchanged. Put another way, a change in the orientation of the OPEP device 100 may increase or decrease the incline of the channel 118 the air flow regulator 120 must traverse to arrive at the second position. Thus, the orientation of the channel 118, along with the position of the air flow regulator 120 within the channel 118, could prevent the air flow regulator 120 from sufficiently restricting the flow of air through the channel 118, such that the administration of OPEP therapy would not be suitable and/or ideal, or alternatively, altogether impossible.
One advantage of the OPEP device 100 is its ability to reduce the effect of the orientation of the OPEP device 100 on the effective administration of OPEP therapy. More specifically, as the housing 102 is rotated about the axis defined between the cylindrical support surfaces 166, gravity acting on the secondary weight 172 in the adjustment band 163 causes the channel assembly 116, and thus the channel 118, to rotate relative to the housing 102 to a position where the secondary weight 172 is below the axis between the cylindrical support surfaces 166. To aid in the creation of a seal, yet maintain mobility of the channel assembly 116, the support surfaces 166 and the inner and outer bushings 162, 164 may be made of suitable low friction materials (e.g., acetyl, nylon, etc.). Alternatively, a lubricant could be applied to the supporting surfaces 166 and the inner and outer bushings 162, 164. In this way, the orientation of the channel assembly 116 does not substantially change as the orientation of the housing 102 is rotated about the axis defined between the cylindrical support surfaces 166. To the extent the orientation of the housing 102 is rotated about the axis perpendicular to the axis defined between the cylindrical support surfaces 166, the orientation indicator 158 provides the user with visual feedback of suitable and/or ideal orientations for the administration of OPEP therapy, as explained below.
The OPEP device 100 is also selectively adjustable to obtain the desired operating conditions of the OPEP therapy. As previously explained, the oscillation frequency and the amplitude of the OPEP therapy is dependent upon, amongst other variables, the angle of the channel 118 that contacts the air flow regulator 120, the normal force supplied by the channel 118 against the air flow regulator 120, and the direction of gravity relative thereto.
As shown in
In
Referring now to
The nebulizer port 110 may also include a one-way valve (not shown) configured to open on inhalation and close on exhalation. In this configuration, an inhalation flow path is formed between the nebulizer port 110 and the chamber inlet 104 via the chamber 114. If the OPEP device 100 is connected to a nebulizer, an aerosol medicament may be drawn from the nebulizer into the respiratory system of the user upon inhalation. If the OPEP device 100 is not connected to a nebulizer, the user may inhale through the nebulizer port 110 the air surrounding the OPEP device 100, or air from a stand-alone air supply connected to the nebulizer port 110. However, in both cases, exhaled air is forced to traverse the channel 118 and exit the OPEP device 100 through the chamber outlet 106. Alternatively, the OPEP device 100 may include a separate inhalation valve (not shown) or omit the nebulizer port 110 altogether, in which case the user would have to inhale through a source external to the OPEP device 100, such as through his or her nose. Notably, the inhalation flow path from the nebulizer port 110 to the mouthpiece 108 bypasses the channel 118, thereby reducing the potential for loss of expensive medicament.
As illustrated in
As shown in
The capsule 178 may be connected to the OPEP device 100 such that movement of the OPEP device 100 within the predetermined range of orientations causes the indicator 158 to remain in a portion of the capsule 178 near the coplanar bases, thus indicating a suitable and/or ideal orientation of the OPEP device 100 for the administration of OPEP therapy. Likewise, the capsule 178 may be shaped and connected to the OPEP device 100 such that movement of the OPEP device 100 within a separate predetermined range of orientations causes the indicator 158 to move to a portion of the capsule 178 near either tip of one of the pair of cones, thereby indicating an orientation of the OPEP device 100 not suitable or ideal for the administration of OPEP therapy. As a further aid to the user, the capsule 178 may include an indicia identifying the portion of the capsule 178 in which the presence of the indicator 158 indicates an orientation of the OPEP device 100 suitable and/or ideal for the administration of OPEP therapy. In
An illustration of the visual feedback provided by the orientation indicator 158 is shown in
Alternatively, as shown in
Turning to
As shown in
Referring now to
In general, the operating components of the orientation indicator 200 comprise a micro electro-mechanical gyroscope 204, a power source 206, one or more visual or auditory indicators 208, 210, and a circuit 212 for connecting all of the same and analyzing the output of the gyroscope 204. These operating components are mounted on a circuit board 214.
Those skilled in the art will appreciate that the micro electro-mechanical gyroscope 204 may be selected from any number of commercially available products, and the power source 206 may be selected from any number of commercially available batteries. Likewise, the one or more visual indicators may be selected from any number of lighting products, such as, for example, one or more different colored light emitting diodes. Similarly, the one or more auditory indicators may by selected from any number of audio signaling devices, including buzzers, beepers, bells, alarms, speakers, or the like.
In operation, the orientation indicator 200 may be connected to the housing 102 of the OPEP device 100 and configured in any number of ways for indicating an orientation of the housing 102 of the OPEP device 100 predetermined to be suitable and/or ideal for administration of OPEP therapy to a user. For example, the one or more visual indicators may include a green light configured to illuminate when the housing 102 of the OPEP device 100 is in a position predetermined to be suitable for administration of OPEP therapy. Or, the one or more visual indicators may also include a red light configured to illuminate when the housing 102 of the OPEP device 100 is in a position predetermined to be less suitable for the administration of OPEP therapy. Alternatively, the illumination of a single light may indicate a suitable or less suitable position of the housing 102. Similarly, the orientation indicator 200 may provide one or more auditory indicators, such as a beep or a warning tone, indicative of a suitable or a less suitable position of the housing 102. Likewise, any combination or variation of the above examples may be used to indicate the suitability of a particular orientation of the housing.
As previously explained, the suitable and/or ideal operation of the OPEP device 100 may be maintained when the OPEP device 100 is rotated about the axis defined between the cylindrical support surfaces 166. However, when the OPEP device 100 is rotated perpendicular to the axis defined between the cylindrical support surfaces 166, the desired and/or ideal operating conditions are impacted, such that visual or auditory feedback from an orientation indicator becomes relevant. Likewise, for any respiratory device that may benefit from the device's orientation for suitable and/or ideal operation, it is envisioned that the orientation indicators described above would provide users with visual or auditory feedback indicative of suitable and/or ideal orientations for a device's operation. Examples of other respiratory devices on which the orientation indicators described above may be mounted include nebulizers, pressurized metered dose inhalers, aerosol holding chambers, peak flow meters and so on.
For example, the orientation indicators described above may be utilized on other commercially available OPEP devices.
In another example, the orientation indicators described above may be utilized on commercially available nebulizers.
The foregoing description has been presented for purposes of illustration and description, and is not intended to be exhaustive or to limit the inventions to the precise forms disclosed. It will be apparent to those skilled in the art that the present inventions are susceptible of many variations and modifications coming within the scope of the following claims. For example, multiple orientation indicators may be utilized on devices whose suitable and/or ideal operation is impacted by movement of the device about more than one axis of rotation. Alternatively, the geometry of a capsule enclosing an orientation indicator on such a device may be configured such that the orientation indicator is capable of moving in more than one direction, thereby providing a more dynamic indication of the suitability of the orientation of the device
This application is a continuation of U.S. application Ser. No. 14/843,662, filed on Sep. 2, 2015, pending, which is a continuation of U.S. application Ser. No. 13/154,103, filed on Jun. 6, 2011, now U.S. Pat. No. 9,149,589, which is a continuation-in-part of U.S. application Ser. No. 12/711,032, filed on Feb. 23, 2010, now U.S. Pat. No. 8,485,179, which claims the benefit of U.S. Provisional Application No. 61/154,661, filed on Feb. 23, 2009, and U.S. Provisional Application No. 61/181,200, filed on May 26, 2009, all of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
393869 | Warren | Dec 1888 | A |
938808 | Yount | Nov 1909 | A |
2670739 | NcNeill | Mar 1954 | A |
2918917 | Emerson | Dec 1959 | A |
3710780 | Milch | Jan 1973 | A |
3908987 | Boehringer | Sep 1975 | A |
4054134 | Kritzer | Oct 1977 | A |
4062358 | Kritzer | Dec 1977 | A |
4182366 | Boehringer | Jan 1980 | A |
4198969 | Virag | Apr 1980 | A |
4221381 | Ericson | Sep 1980 | A |
4226233 | Kritzer | Oct 1980 | A |
4231375 | Boehringer et al. | Nov 1980 | A |
4267832 | Hakkinen | May 1981 | A |
4275722 | Sorensen | Jun 1981 | A |
4298023 | McGinnis | Nov 1981 | A |
4327740 | Shuman | May 1982 | A |
4403616 | King | Sep 1983 | A |
4436090 | Darling | Mar 1984 | A |
4470412 | Nowacki et al. | Sep 1984 | A |
4601465 | Roy | Jul 1986 | A |
4611591 | Inui et al. | Sep 1986 | A |
4635631 | Izumi | Jan 1987 | A |
4651731 | Vicenzi et al. | Mar 1987 | A |
4739987 | Nicholson | Apr 1988 | A |
4770413 | Green | Sep 1988 | A |
4899370 | Kameo et al. | Feb 1990 | A |
4951661 | Sladek | Aug 1990 | A |
4973047 | Norell | Nov 1990 | A |
4981295 | Belman et al. | Jan 1991 | A |
5018517 | Liardet | May 1991 | A |
5042467 | Foley | Aug 1991 | A |
5065746 | Steen | Nov 1991 | A |
5193529 | Labaere | Mar 1993 | A |
5345930 | Cardinal et al. | Sep 1994 | A |
5372128 | Haber et al. | Dec 1994 | A |
5381789 | Marquardt | Jan 1995 | A |
5451190 | Liardet | Sep 1995 | A |
5479920 | Piper et al. | Jan 1996 | A |
5540220 | Gropper et al. | Jul 1996 | A |
5569122 | Cegla | Oct 1996 | A |
5570682 | Johnson | Nov 1996 | A |
5598839 | Niles et al. | Feb 1997 | A |
5613489 | Miller | Mar 1997 | A |
5645049 | Foley et al. | Jul 1997 | A |
5647345 | Saul | Jul 1997 | A |
5655520 | Howe | Aug 1997 | A |
5658221 | Hougen | Aug 1997 | A |
5727546 | Clarke et al. | Mar 1998 | A |
5791339 | Winter | Aug 1998 | A |
5829429 | Hughes | Nov 1998 | A |
5848588 | Foley et al. | Dec 1998 | A |
5862802 | Bird | Jan 1999 | A |
5890998 | Hougen | Apr 1999 | A |
5893361 | Hughes | Apr 1999 | A |
5899832 | Hougen | May 1999 | A |
5910071 | Hougen | Jun 1999 | A |
5925831 | Storsved | Jul 1999 | A |
5957125 | Sagstetter et al. | Sep 1999 | A |
5988166 | Hayek | Nov 1999 | A |
6026807 | Puderbaugh et al. | Feb 2000 | A |
6029661 | Whaley et al. | Feb 2000 | A |
6044841 | Verdun et al. | Apr 2000 | A |
6058932 | Hughes | May 2000 | A |
6066101 | Johnson | May 2000 | A |
6067984 | Piper | May 2000 | A |
6083141 | Hougen | Jul 2000 | A |
6089105 | Ricciardelli | Jul 2000 | A |
6102038 | DeVries | Aug 2000 | A |
6167881 | Hughes | Jan 2001 | B1 |
6176235 | Benarrouch et al. | Jan 2001 | B1 |
6182657 | Brydon et al. | Feb 2001 | B1 |
D440651 | Foran | Apr 2001 | S |
6240917 | Andrade | Jun 2001 | B1 |
6253766 | Niles | Jul 2001 | B1 |
6269839 | Wickham et al. | Aug 2001 | B1 |
6293279 | Schmidt et al. | Sep 2001 | B1 |
6340025 | Van Brunt | Jan 2002 | B1 |
6345617 | Engelbreth et al. | Feb 2002 | B1 |
6412481 | Bienvenu et al. | Jul 2002 | B1 |
6446629 | Takaki et al. | Sep 2002 | B1 |
6447459 | Larom | Sep 2002 | B1 |
6500095 | Hougen | Dec 2002 | B1 |
6557549 | Schmidt et al. | May 2003 | B2 |
6581595 | Murdock et al. | Jun 2003 | B1 |
6581596 | Truitt | Jun 2003 | B1 |
6581598 | Foran et al. | Jun 2003 | B1 |
6581600 | Bird | Jun 2003 | B2 |
6595203 | Bird | Jul 2003 | B1 |
6606989 | Brand | Aug 2003 | B1 |
6607008 | Yoshimoto et al. | Aug 2003 | B1 |
6615831 | Truitt | Sep 2003 | B1 |
6631721 | Salter et al. | Oct 2003 | B1 |
6659100 | O'Rourke | Dec 2003 | B2 |
6681768 | Haaije de Boer et al. | Jan 2004 | B2 |
6702769 | Fowler-Hawkins | Mar 2004 | B1 |
6708690 | Hete et al. | Mar 2004 | B1 |
6708691 | Hayek | Mar 2004 | B1 |
6726598 | Jarvis | Apr 2004 | B1 |
D490519 | Pelerossi et al. | May 2004 | S |
6776159 | Pelerossi et al. | Aug 2004 | B2 |
6848443 | Schmidt et al. | Feb 2005 | B2 |
6851425 | Jaffre | Feb 2005 | B2 |
6904906 | Salter | Jun 2005 | B2 |
6923181 | Tuck | Aug 2005 | B2 |
6929007 | Emerson | Aug 2005 | B2 |
6984214 | Fowler-Hawkins | Jan 2006 | B2 |
7059324 | Pelerossi et al. | Jun 2006 | B2 |
7096866 | Be'eri et al. | Aug 2006 | B2 |
7134434 | Truitt et al. | Nov 2006 | B2 |
7165547 | Truitt et al. | Jan 2007 | B2 |
7188621 | DeVries | Mar 2007 | B2 |
7191776 | Niles | Mar 2007 | B2 |
7191780 | Faram | Mar 2007 | B2 |
7214170 | Summers et al. | May 2007 | B2 |
7383740 | Krasilchikov et al. | Jun 2008 | B2 |
7617821 | Hughes | Nov 2009 | B2 |
7699054 | Pelerossi et al. | Apr 2010 | B2 |
7717847 | Smith | May 2010 | B2 |
7771472 | Hendricksen | Aug 2010 | B2 |
7779841 | Dunsmore et al. | Aug 2010 | B2 |
7798148 | Doshi | Sep 2010 | B2 |
7856979 | Doshi | Dec 2010 | B2 |
7905228 | Blacker et al. | Mar 2011 | B2 |
7909033 | Faram | Mar 2011 | B2 |
8006922 | Katzer | Aug 2011 | B2 |
8025051 | Dagsland | Sep 2011 | B2 |
8025054 | Dunsmore et al. | Sep 2011 | B2 |
8043236 | Goldshtein et al. | Oct 2011 | B2 |
8051854 | Faram | Nov 2011 | B2 |
RE43174 | Schmidt et al. | Feb 2012 | E |
8118024 | DeVries et al. | Feb 2012 | B2 |
8118713 | Foley et al. | Feb 2012 | B2 |
8225785 | Richards et al. | Jul 2012 | B2 |
8327849 | Grychowski et al. | Dec 2012 | B2 |
8360061 | Brown | Jan 2013 | B2 |
8460223 | Huster et al. | Jun 2013 | B2 |
8469029 | Brown et al. | Jun 2013 | B2 |
8485179 | Meyer | Jul 2013 | B1 |
8528547 | Dunsmore | Sep 2013 | B2 |
8539951 | Meyer et al. | Sep 2013 | B1 |
8985111 | Grychowski et al. | Mar 2015 | B2 |
8993774 | Kanbara et al. | Mar 2015 | B2 |
D731050 | Meyer | Jun 2015 | S |
9149589 | Meyer et al. | Oct 2015 | B2 |
9220855 | Meyer | Dec 2015 | B2 |
9358417 | Meyer | Jun 2016 | B2 |
9517315 | Meyer | Dec 2016 | B2 |
D776804 | Meyer | Jan 2017 | S |
D778429 | Engelbreth et al. | Feb 2017 | S |
D780906 | Engelbreth et al. | Mar 2017 | S |
9636473 | Meyer | May 2017 | B2 |
9737677 | Grychowski et al. | Aug 2017 | B2 |
9808588 | Meyer et al. | Nov 2017 | B1 |
9849257 | Meyer et al. | Dec 2017 | B2 |
9913955 | Grychowski et al. | Mar 2018 | B2 |
9950128 | Meyer et al. | Apr 2018 | B2 |
9981106 | Meyer et al. | May 2018 | B2 |
10039691 | Von Hollen | Aug 2018 | B2 |
10076616 | Meyer et al. | Sep 2018 | B2 |
10272224 | Costella et al. | Apr 2019 | B2 |
10363383 | Alizoti et al. | Jul 2019 | B2 |
10413698 | Meyer et al. | Sep 2019 | B2 |
10449324 | Meyer et al. | Oct 2019 | B2 |
10589043 | Meyer et al. | Mar 2020 | B2 |
10668235 | Meyer et al. | Jun 2020 | B2 |
20050253727 | Gonzalez | Nov 2005 | A1 |
20060032607 | Wisniewski | Feb 2006 | A1 |
20070017506 | Bell et al. | Jan 2007 | A1 |
20070089740 | Baumert et al. | Apr 2007 | A1 |
20070193582 | Kwok et al. | Aug 2007 | A1 |
20070259759 | Sumners et al. | Nov 2007 | A1 |
20080078384 | Messenger et al. | Apr 2008 | A1 |
20080257348 | Piper | Oct 2008 | A1 |
20090241949 | Smutney et al. | Oct 2009 | A1 |
20100077866 | Graboi et al. | Apr 2010 | A1 |
20100139655 | Genosar | Jun 2010 | A1 |
20100207774 | Song | Aug 2010 | A1 |
20100307487 | Dunsmore et al. | Dec 2010 | A1 |
20120097164 | Rozario et al. | Apr 2012 | A1 |
20120190969 | Kameli | Jul 2012 | A1 |
20150374939 | Meyer et al. | Dec 2015 | A1 |
20170049979 | Meyer et al. | Feb 2017 | A1 |
20170128683 | Meyer et al. | May 2017 | A1 |
20170312461 | Grychowski et al. | Nov 2017 | A1 |
20180154093 | Meyer et al. | Jun 2018 | A1 |
20180214662 | Meyer et al. | Aug 2018 | A1 |
20180256839 | Meyer et al. | Sep 2018 | A1 |
20190240533 | Alizoti | Aug 2019 | A1 |
Number | Date | Country |
---|---|---|
0 372 148 | Jun 1990 | EP |
0 678 306 | Oct 1995 | EP |
1 464 357 | Oct 2004 | EP |
1 435 251 | Jun 2006 | EP |
1 103 287 | Jun 2007 | EP |
1 897 576 | Mar 2008 | EP |
1 908 489 | Apr 2008 | EP |
2444114 | Apr 2012 | EP |
2455137 | May 2012 | EP |
2 425 488 | Nov 2006 | GB |
WO 198903707 | May 1989 | WO |
WO 199640376 | Dec 1996 | WO |
WO 199916490 | Apr 1999 | WO |
WO 200027455 | May 2000 | WO |
WO 2007061648 | May 2007 | WO |
WO 2007119104 | Oct 2007 | WO |
WO 2008063966 | May 2008 | WO |
WO 2008122045 | Oct 2008 | WO |
WO 2009131965 | Oct 2009 | WO |
WO 2011058470 | May 2011 | WO |
WO 2012038864 | Mar 2012 | WO |
WO 2016012740 | Jan 2016 | WO |
Entry |
---|
U.S. Appl. No. 14/674,494, filed Mar. 31, 2015, Meyer et al. |
Web page entitled Bronchial Hygiene, acapella Vibratory PEP Therapy System accessed from http://www.smiths-medical.com/catalog/bronchial-hygiene/acapella/acapella.html on Jul. 7, 2009. |
Web page entitled Thayer Quake accessed from http://www.thayermedical.com/quake.htm on Jul. 7, 2009. |
Human growth hormone, cortisol, and acid-base balance changes after hyperventilation and breath-holding; PubMed—indexed for MEDLINE; Int J Sports Med., Dec. 1986; 7(6):311-5, Djarova T. |
Bosco C, Cardinale M. & Tsarpela O (1999). Influence of vibration on mechanical power and electromyogram activity in human arm flexor muscles. Eur J Appl Physiol 79, 306-311. |
David Sumners; Power Breathing and Strength; http://EzineArticles.com/972576 Published: Feb. 7, 2008. |
Good Vibrations blog; http://vibrotraining.blogspot.com, Earliest posting Jan. 17, 2008. |
Breathtaking News; More Youbreathe; Aug. 10, 2007. |
PCT International Search Report for PCT/IB2012/001089, dated Oct. 5, 2012. |
PCT International Written Opinion for PCT/IB2012/001089, dated Oct. 5, 2012. |
Preliminary Report on Patentability, PCT/IB2012/001089, dated Dec. 10, 2013. |
PCT/IB2012001089 European Search Report dated Nov. 6, 2014. |
IPR2018/01025 Petition; D R Burton Healthcare LLC v. Trudell Medical International; Title: Oscillating Positive Respiratory Pressure Device; (94 pp). |
D R Burton Healthcare LLC v. Trudell Medical International; “Patent Owner's Preliminary Response to Petition for Inter Partes Review”; Case No. IPR2018/01025, U.S. Pat. No. 9,808,588; Sep. 7, 2018; 107 pages. |
D R Burton Healthcare LLC v. Trudell Medical International; “Declaration of Dr. William W. Durgin, Ph.D., In Support of Patent Owner's Preliminary Response to Petition tor Inter Partes Review”; Case No. IPR2018/01025, U.S. Pat. No. 9,808,588; Trudell Medical Exhibit 2001/00001-2001/00217; 217 pages. |
D R Burton Healthcare LLC v. Trudell Medical International; “Petitioner's Reply to Patent Owner Preliminary Response”; Case No. IPR2018/01025, U.S. Appl. No. 9,808,588 B1; Oct. 9, 2018; 16 pages. |
D R Burton Healthcare LLC v. Trudell Medical International; “Decision Denying Institution of Inter Partes Review”; Case No. IPR2018/01025, U.S. Pat. No. 9,808,588 B1; Nov. 29, 2018; 32 pages. |
Number | Date | Country | |
---|---|---|---|
20200384222 A1 | Dec 2020 | US |
Number | Date | Country | |
---|---|---|---|
61181200 | May 2009 | US | |
61154661 | Feb 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14843662 | Sep 2015 | US |
Child | 16912213 | US | |
Parent | 13154103 | Jun 2011 | US |
Child | 14843662 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12711032 | Feb 2010 | US |
Child | 13154103 | US |